alexa IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Pharmaceutical Sciences

Pharmaceutical Sciences

Biochemistry & Pharmacology: Open Access

Author(s): Bose A, Baral R

Abstract Share this page

Abstract Interferonalpha2b (IFNalpha2b) augments the suppressed immune functions and peripheral blood mononuclear cell (PBMC) cytotoxicity of head and neck squamous cell carcinoma (HNSCC) patients by differential regulation of IFNgamma, a pleotropic Th1 cytokine. In the present communication, we have examined the role of IFNgamma in IFNalpha2b initiated T and NK cell mediated cytotoxicity of tumor cells. IFNalpha2b activates both T and NK cells to release IFNgamma. IFNgamma plays a crucial role in enhancing tumor cell cytotoxicity by T cells, but not by NK cells, as evidenced by killing of a oral (KB) and breast (MCF7) cancer cells, without affecting the killing of NK sensitive erythroleukemic K562 cells by IFNalpha2b activated PBMC. IFNalpha2b driven tumor cell cytotoxicity is related to the rectification of the downregulated expression of cytotoxic molecules, perforin, granzyme B and FasL in CD8+ T and CD56+ NK cells. Expression of IFNalpha2b mediated perforin and granzyme B is dependent on IFNgamma in T cells, but not in NK cells. However, expression of FasL in both T and NK cells is not dependent on IFNgamma. In conclusion, IFNalpha2b enhances suppressed T cell cytotoxicity of HNSCC patients by stimulating perforin-granzyme B system, which is IFNgamma dependent. IFNalpha2b also induces the expression of perforin-granzyme B system in NK cells, but this NK mediated cytotoxicity is IFNgamma independent. This article was published in Immunol Lett and referenced in Biochemistry & Pharmacology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords